Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said.
The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments